Inhibrx Biosciences, Inc. INBX
86.76 USD 0.00 (+0.00%)
At closeNov 5, 2026, 7:56 AM EST
87.98 +1.22 +1.41%
Pre-market · Nov 5, 7:56 AM ET
82.13 Day range 87.13
57.30 52-week range 155.29
- YTD
- +9.82%
- 1 year
- +5.82%
- Market cap
- 1.28B
- EPS (ttm)
- -8.88
- Shares out
- 14.72M
- Forward P/E
- -9.90
- YTD return
- +9.82%
- 1-year return
- +5.82%
- Volume
- 190.18K
- Avg volume
- 310.06K
- Open
- 83.95
- Previous close
- 86.76
- Day's range
- 82.13 – 87.13
- 52-week range
- 57.30 – 155.29
- Beta
- 4.04
- Analysts
- Strong Buy
- Price target
- 266.67 (+207.4%)
- Earnings date
- Nov 13, 2026
1m +3.35 (+4.02%)
Key statistics
- Enterprise value
- 1.24B
- PEG ratio
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -85.10M
- Total cash
- 133.34M
- Total debt
- 181.63M
- Return on equity
- -1773.60%
- Short % of float
- 31.00%
- 50-day average
- 101.24
- 200-day average
- 92.18
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 266.67 +207.4% upside
Now 86.76
- Target (low)
- 230.00
- Target (mean)
- 266.67
- Target (high)
- 325.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
- Strong buy0
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 13, 2026
Expected Nov 13, 2026. Consensus EPS estimate -2.36.
Financials — quick view
INBX Revenue — quarterly 0
INBX Net income — quarterly -36.65M
INBX EPS — quarterly -2.34
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2026 | Sep 30, 2026 | -2.45 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -2.28 | -2.34 | -0.06 | -2.63% |
| May 14, 2026 | Mar 31, 2026 | -2.37 | -2.15 | +0.22 | +9.28% |
| Mar 19, 2026 | Dec 31, 2025 | -2.08 | -2.11 | -0.03 | -1.44% |
| Nov 14, 2025 | Sep 30, 2025 | -2.08 | -2.28 | -0.20 | -9.62% |
| Aug 13, 2025 | Jun 30, 2025 | -2.92 | -1.85 | +1.07 | +36.64% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 24, 2026 | HC Wainwright & Co. | init | — | Buy |
| Apr 8, 2026 | Stifel | init | — | Buy |
| Aug 22, 2025 | JMP Securities | reit | Market Perform | Market Perform |
| May 15, 2025 | JMP Securities | reit | Market Perform | Market Perform |
| Mar 18, 2025 | Citizens Capital Markets | reit | Market Perform | Market Perform |
| Jan 22, 2025 | JMP Securities | reit | Market Perform | Market Perform |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- inhibrx.com
News
12 Health Care Stocks Moving In Wednesday's Intraday Session 
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates 
Inhibrx To Present Phase 2 INBRX-106 HNSCC Results On Webcast Live On Tuesday, September 8 At 5:00 a.m. PT 
HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245 
Inhibrx Biosciences Says FDA Accepts BLA Seeking Approval Of Ozekibart In Patients With Conventional Chondrosarcoma; PDUFA Goal Date Set For April 14, 2027 
Inhibrx Biosciences Q1 EPS $(2.15) Misses $(1.79) Estimate 
Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study 
Inhibrx Reports Interim Phase 2 Data For INBRX-106 in First-Line HNSCC - 12 Health Care Stocks Moving In Friday's After-Market Session
- Inhibrx Biosciences To Present Interim Phase 2 HexAgon Study Results For INBRX-106 Plus Keytruda In Head And Neck Cancer On May 11, 2026 Webcast
Your note
Sign in to keep a note on INBX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FORSYTH DOUGLAS | Director | Purchase | Sep 7, 2026 | 0 |
| KAYYEM JON FAIZ | Director | Purchase | Sep 22, 2026 | 0 |
| LAPPE MARK | Chief Executive Officer | Purchase | Oct 13, 2026 | 0 |
| MANHARD KIMBERLY J | Director | Sale | Sep 14, 2026 | 0 |
| VIKING GLOBAL INVESTORS LP | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 6, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Morgan Stanley | 8.89% | 1,308,051 | 113.49M | Jun 29, 2026 |
| Perceptive Advisors Llc | 8.82% | 1,297,763 | 112.59M | Jun 29, 2026 |
| Sanofi | 7.87% | 1,157,926 | 100.46M | Jun 29, 2026 |
| Viking Global Investors, L.P. | 7.64% | 1,123,929 | 97.51M | Jun 29, 2026 |
| HighTower Advisors, LLC | 5.92% | 870,551 | 75.53M | Jun 29, 2026 |
| Bank of America Corporation | 5.72% | 841,141 | 72.98M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.51% | 369,641 | 32.07M | Jun 29, 2026 |
| SmallCap World Fund Inc | 2.40% | 353,292 | 30.65M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.21% | 324,794 | 28.18M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.68% | 247,839 | 21.50M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.75% | 109,883 | 9.53M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.71% | 103,938 | 9.02M | Aug 30, 2026 |